Ascendis Pharma (ASND) Stock Chart - Revenue & Earnings | Quarter Chart
Revenue by Product
Revenue by Geography
Revenue, Gross Profit, Operating and Net Income
Margin (%)
Operating Expenses
EBITDA
EPS
Revenue Variation (%)
Income Variation (%)
Revenue YoY Variation (%)
Income YoY Variation (%)
Price-to-Earning Ratio
Income Breakdown
Per Share Metrics
Expense Ratios
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt Ratio
Current Ratio
Quick Ratio
Cash & Equivalents
Total Assets
Total Liabilities
Shareholders Equity
Asset Composition
Debt Structure
Ascendis Pharma (ASND) quarterly earnings & revenue
Ascendis Pharma (ASND) reported revenue of $291.77M for Q1 2026, up 148.3% year-over-year, with net income of $744.62M and diluted EPS of $11.54.
Over the last four reported quarters, Ascendis Pharma generated $1.01B in revenue and $589.70M in net income.
Ascendis Pharma's next earnings report is scheduled for August 6, 2026 after market close; analysts estimate EPS of $1.27.
Ascendis Pharma quarterly results
| Fiscal quarter | Revenue | Revenue YoY | Net income | EPS (diluted) |
|---|---|---|---|---|
| Q1 2026 | $291.77M | +148.3% | $744.62M | $11.54 |
| Q4 2025 | $285.40M | +41.0% | $-38.70M | $-0.63 |
| Q3 2025 | $248.68M | +269.4% | $-70.99M | $-1.16 |
| Q2 2025 | $183.97M | +339.0% | $-45.23M | $-0.95 |
| Q1 2025 | $117.51M | +5.3% | $-110.15M | $-1.84 |
| Q4 2024 | $202.45M | +26.3% | $-44.78M | $-0.74 |
| Q3 2024 | $67.32M | +20.4% | $-115.47M | $-1.97 |
| Q2 2024 | $41.90M | -24.0% | $-127.32M | $-2.22 |
Ascendis Pharma (ASND) — frequently asked questions
When does Ascendis Pharma (ASND) report earnings next?
Ascendis Pharma is expected to report earnings on August 6, 2026 after market close. Analysts estimate EPS of $1.27.
What was ASND's revenue last quarter?
Ascendis Pharma reported revenue of $291.77M in Q1 2026, up 148.3% from the same quarter a year earlier.
What was ASND's EPS last quarter?
Ascendis Pharma reported diluted EPS of $11.54 in Q1 2026.
Is Ascendis Pharma profitable?
Ascendis Pharma is currently profitable, with $589.70M in net income over the last four reported quarters.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Roche (ROG.SW) · Merck (MRK)